Compare Neurocrine Biosciences Inc (NBIX) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Roundhill NVDA WeeklyPay ETF — how do they compare? Neurocrine Biosciences Inc trades at $156.22 (market cap $16.46B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | NVDW | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $185.50 | $52.59 |
52-Week Low | $123.10 | $31.88 |
Enterprise Value | $16.48B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
NVDW, trading at $38.53, gained 3.21% in the last session with a bullish technical signal driven by moving averages. The stock exhibits strong weekly dividend activity, with recent payouts ranging from $0.13 to $0.48, indicating a focus on income generation. Key resistance lies near $39, while support is established around $36–37.
The outlook hinges on NVDW's ability to sustain its dividend strategy amid market volatility. Risks include payout consistency and reliance on underlying asset performance. Opportunities exist for income-focused investors, but cautious monitoring of technical overbought signals is warranted.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
